Overview
- Hugel said at the J.P. Morgan Healthcare Conference it will introduce a U.S. hybrid sales approach later this year, adding direct sales while keeping its distributor relationship.
- The company targets KRW900 billion in annual net sales by 2028 with the United States accounting for at least 30 percent of total revenue.
- Letybo, launched in the U.S. in March 2025, has captured roughly a 3 percent share, with goals of about 10 percent by 2028 and 14 percent by 2030.
- CEO Carrie Strom said a small direct team will focus on key accounts and work alongside BENEV to drive higher average selling prices and improve margins.
- Planned growth initiatives include skin boosters in Australia this year, leveraging a 50‑unit vial in China, and potential Letybo launches in new markets such as Saudi Arabia, Turkey and Mexico within two years.